Bioinformatics Analysis of the Regulatory IncRNA-miRNA-mRNA Network in Patients with Neuropathic Pain

Huai-Gen Zhang  
First Affiliated Hospital of Nanchang University

Li Liu  
Jiangxi Provincial People's Hospital

Zhi-Ping Song  
First Affiliated Hospital of Nanchang University

Da-Ying Zhang (✉ zhang-daying791@outlook.com)  
First Affiliated Hospital of Nanchang University  https://orcid.org/0000-0002-7745-9122

Research article

Keywords: neuropathic pain, IncRNA-miRNA-mRNA network, KEGG, bioinformatics, protein-protein interaction analysis

Posted Date: August 17th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-54799/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Neuropathic pain (NP) is the main form of chronic pain, caused by damage to the nervous system and dysfunction.

Methods: Here, we explore the key molecules involved in the development of NP condition via identification of IncRNA-miRNA-mRNA expression pattern of patients with NP. We identified differentially expressed miRNAs, IncRNA and mRNA through a comprehensive analysis strategy. Subsequently, we used bioinformatics approach to perform pathway enrichment analysis on DEGs and protein-protein interaction analysis. Combined with the three datasets, the IncRNA-miRNA-mRNA network was constructed. It will then be used as targets for drug prediction.

Results: The results showed that a total of 8,251 DEGs (4,193 upregulated and 4,058 downregulated) were identified from the three microarray datasets, 959 DEmiRs (455 upregulated and 504 downregulated), 2,848 DEInc (1,324 upregulated and 1,524 downregulated). GO analysis showed that DEGs are mainly enriched in blood circulation, regulation of membrane potential and regulation of ion transmembrane transport. KEGG results showed that DEGs are enriched in neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway and MAPK signaling pathway. When the correlation is set to above 0.8, a total of 31 IncRNAs, 36 miRNAs and 24 mRNAs were screened in the IncRNA-miRNA-mRNA network. The results of drug prediction indicated the targeted drugs mainly include INDOMETHACIN, GLUTAMIC ACID and PIRACETAM.

Conclusion: The IncRNA-miRNA-mRNA network has been carried out a comprehensive biological information analysis and predicted the potential therapeutic application of drugs in patients with NP. The corresponding data has a certain reference for studying the pathological mechanism of NP.

Background

Neuropathic pain (NP), the main form of chronic pain, is caused by damage to the nervous system and dysfunction (1, 2). Currently, the treatment of NP is limited to symptomatic treatment. However, the prognosis of NP is poor. To better understand the pathogenesis of NP, it is essential to develop effective prevention strategies and improve the efficacy of NP. To deepen the genetic and various neurobiological bases of NP, it can provide important diagnostic and therapeutic tools for clinicians.

Long non-protein-coding RNA (lncRNA) is a transcript that is more than 200 nucleotide (nt) long. LncRNAs can regulate a variety of processes, including DNA methylation, staining structure, transcription and post-transcription RNA treatment. LncRNAs can be involved in various gene transcriptional processes via interacting with transcription factors, coactivators and/or inhibitors. Accumulating evidences showed that LncRNAs play roles in the pathogenesis of nervous system disease (3, 4). For instance, Zhou, Xiong (5) found that a total of 134 LncRNAs, 12 miRNAs, 188 circRNAs and 1066 mRNAs were significantly regulated after SNI surgery. The function analysis has also indicated that the pathogenesis of SNI was enriched in ribosome and ECM-receptor interaction. All this information will contribute to the study on NP
pathogenesis. Wei, Li (3) found that IncRNA X inactive-specific transcript (XIST) promotes NP progression in rats via down-regulation of miR-154-5p and up-regulation of TLR5s, representing a novel therapeutic target in NP treatment.

MicroRNAs (miRNAs), non-coding RNAs, regulate gene expression and can be often used as potential biomarkers. Dayer, Luthi (6) reported that chronic pain may induce the abnormal, specific dysregulation of miRNA expression and they found that hsa-miR-320a and hsa-miR-98-5p (two c-miRNA signatures) can serve as a biomarker for pain-type classification. The epigenetic intervention of miRNA may also be a new therapeutic approach for complications such as injurious hypersensitivity caused by peripheral nerve injury. Pan, Shan (7) reported that miR-23a regulates the NP through the TXNIP/NLRP3 inflammasome axis in spinal glial cells targeting directly with CXCR4, suggesting a potential target for NP treatment.

With the rapid development of high-throughput sequencing, data mining, and the wide application of precision medicine, it becomes more feasible to extract aberrant data of ncRNAs and mRNAs on neuropathic pain from the microarray datasets. Although previous investigations have been reported the role of some ncRNAs in regulation of NP pathological pathways, the pathogenesis of NP has yet been fully understood. Therefore, in this study, in combination with bioinformatics and transcriptomics, three datasets from GEO (GSE107180, GSE145199 and GSE24982) were downloaded to identify differentially expressed mRNAs, miRNAs and IncRNAs. We then performed GO and KEGG functional enrichment analysis of differentially expressed mRNAs and the protein-protein interaction (PPI) to investigate gene interactions. Moreover, the IncRNA-miRNA-mRNA network has been constructed for the interaction of tree transcripts in the NP pathological pathway. Our study will contribute to the understanding of NP pathogenesis and providing new strategies for targeted drugs and therapies.

Methods

Raw data collection

The keywords "Neuropathic Pain" and "IncRNA" or "miRNA" or "mRNA" were retrieved using the Integrated Gene Expression Database (GEO, https://www.ncbi.nlm.nih.gov/geo/). Eligible datasets must be met with the following inclusion criteria: 1) A microarray analysis study belonging to human NP patients; 2) The dataset contains NP patients and control samples; 3) Each sample size has a group label; 4) The corresponding gene symbol annotation or gene bank ID of each probe of the microarray in the platform file; 5) The original data is available. The exclusive criteria are as follow: 1) datasets as animal samples or cell columns; 2) non-NP samples 3) non-microarray data types; 4) samples without controls; 5) probes without gene notation or library ID annotation. Finally, this paper filters and downloads GSE107180, GSE145199, and GSE24982 datasets.

Raw data pretreatment and screening for DEInc, DEmiRs and DEGs
The GEO dataset is the mainstream common functional genomics data repository. However, the data uploaded is often crude, incomplete, or noisy. Therefore, the used data are pre-processed before data mining, including data cleaning, data filtering and data normalization processing. For Illumina expression arrays, microarray quality control methods are commonly used for background correction and quantile normalization. This method can eliminate the non-experimental differences caused by technical differences and ensure the comparability of data between different samples. The original signal strength data of GSE107180, GSE145199 and GSE24982 were converted using Illumina package (Version 4.0.1 of R). The limma package was used to identify DElncs, DEmiRs, and DEGs. The gene symbol was annotated to the corresponding probe and calculate the average value of the probes when the gene symbol mapped multiple probes. We used R’s Gplot packages to map the volcanoes of DElncs, DEmiRs and DEGs. R software endpoint "SVa" packages were used to eliminate data heterogeneity and batch effects, and changes in sample types were retained for further analysis of DEGs. The "PheatMap" package of R is used to draw a hierarchical clustering diagram. Finally, we used the mixed variance analysis model with the error discovery rate (Benjamin-Hochberg Test (FDR). The expression levels of RNA molecules with significant differences were screened by using the adjusted P < 0.05 and |log2Fc| value > 1.

Predicting potential IncRNAs and genes

Initially, the identified DmiRs were used to predict IncRNAs. LncRNA-miRNA interactions based on the following three IncRNA target prediction sites, including DIANA-LncBase (Version 2; www.microrna.gr/LncBase), LNCipedia (Version 5.0; http://www.lncipedia.org) and starBase (Version 3.0; http://starbase.sysu.edu.cn/). At least two of these sites do not include the eligible IncRNA and DEmiRs binding sites. The intersection of predicted IncRNAs and identified DElncs was obtained from three websites. The overlapping IncRNA was retained for further analysis. Also, the microRNAs-mRNA pairs was obtained from mirTarBase 7.0 (http://mirtarbase.mbc.nctu.edu.tw/php/index) and TargetScan version 7.1 (http://www.targetscan.org/). According to target prediction, DElncs and DEGs with recognized miRNA binding sites are considered as a potential IncRNA-miRNA-mRNA interaction.

Protein-protein interaction (PPI) network of DEGs, screening for hub genes and IncRNA-miRNA-mRNA network

The Database for Annotation, Visualization and Integrated Discovery (DAVID) integrating annotations, visualization, and integration findings, was used to explore the main functions and pathways of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis (8, 9). The DAVID is an integrated biological database containing gene function classification, pathway mining and clustering tools. These tools were developed to extract systematically biological information from uploaded gene lists. In addition, the Malacards database was used in the analysis in order to ensure the accuracy of the results. Malacards is an integrated database of human diseases with annotations from several noted data sources. Malacards contains fourteen annotated topics, including symptoms, related diseases, summaries, medications and treatments. We adjusted P-value using the Benjamini method or FDR method in multiple test corrections. In addition, P < 0.05 was selected as the threshold and the enrichment score was defined as conversion log 10 (P-value).
A search tool for the retrieval of interacting Genes (https://string-db.org/) is an online functional protein association network. The association in STrinGd is specific and biological, including both direct (physical) and indirect (functional) interactions. We uploaded the DEGs required for analysis to the STrinG and obtained the potential PPI network. The hub genes are key genes that play an important role in a variety of biological processes and often play regulatory roles on the expression of other genes in the related pathways. Therefore, the hub gene is also considered as an important target. Hub genes are screened based on the network topology. CytoHubba is an application for an effective Cytoscape version 3.6.1 (http://www.cyto-scape.org/) that can be used to identify hub genes accurately through twelve topological analysis methods. Cytoscape is an open-source software platform to visualize molecular interaction networks. These networks are mixed with annotations of gene expression profiles and other data. We used Maximal Clique Centrality (Mcc) to identify the top 20 hub genes and input the data of paired lncRNA-miRNA-mRNA into Cytoscape software in order to generate the regulatory network image.

**Drug prediction of DEGs**

The Drug Gene Interaction database, DGIdb (www.dgidb.org) has been used to integrate, organize and display drugs, gene interactions and gene-drug information from published articles and web resources (10). It can be standardized content from 30 different sources and allows to search and filter information. It is easily accessed through an intuitive Web user interface, an application programming interface (API), and publicly cloud-based server images. We uploaded the DEG list identified in the mRNA dataset onto the drugBank to predict their relevance of potential targeted drugs. The aim of this study is to reveal the molecular mechanism of the drugs currently used in NP and provide potential target genes for the development of future drugs.

**Results**

**Detection of DElncs, DEmiRs and DEGs**

After data preprocessing, the raw data of each data set were normalized. The boxplot (Fig. 1) showed the difference of each sample before and after data normalization. The volcano plots (Fig. 2A-2C) described the abnormally expressed RNA molecules in three microarray datasets including GSE107180, GSE145199 and GSE24982. A total of 2,848 DElncs (1,324 upregulated and 1,524 downregulated) were identified in GSE107180. A total of 959 DEmiRs were identified in GSE145199, of which 455 DEGs were upregulated and 504 were downregulated. Finally, 8,251 DEGs (4193 upregulated and 4058 downregulated) were identified in GSE24982. The heatmap (Fig. 2D-2F) displayed the top ten RNAs with the smallest P-values in the upregulated and downregulated clusters in three RNA microarray datasets.

**GO and KEGG functional enrichment analysis of DEGs**

The “clusterProfiler” package was used for GO and KEGG analysis of 8,251 DEGs detected (Fig. 3). GO and KEGG enrichment analysis has a wide range of applications in bioinformatics and can be explained biological mechanisms and functional pathways in genomics and/or transcriptomics. The GO analysis
can be divided into "Biological processes" (BP), "Cellular components" (CC), and "Molecular functions" (MF). The functional analysis indicated that the DEGs were enriched in blood circulation, regulation of membrane potential, regulation of ion transmembrane transport, regulation of metal ion transport, metal ion transmembrane transporter activity, amide binding, gated channel activity, ion gated channel activity, synaptic membrane, postsynaptic specialization, neuron to neuron synapse and asymmetric synapse. Additionally, KEGG analysis showed that they were mainly participated in neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, MAPK signaling pathway, Rap1 signaling pathway, cAMP signaling pathway and Calcium signaling pathway.

Construction of PPI, hub gene and IncRNA-miRNA-mRNA networks

The PPI analysis is to study the molecular mechanism of diseases from a systematic perspective and discover novel drug targets. The PPI network is run on STRING to explore the interactions between the first 50 DEGs encoded proteins. We eliminated the unconnected nodes in the network and finally got 28 nodes and 45 edges (Fig. 4A) in the network. Additionally, Cytoscape was used to integrate the biomolecular interactions of IncRNA-miRNA-mRNAs into a single network.

When the miRNA-mRNA correlation was set to be greater than 0.8, a total of 24 miRNAs were found, which jointly regulated 381 mRNA targets, among which the top five miRNAs that regulated the amount of mRNA were miR-940, miR-200C-3p, miR-5192, miR-2277-3p, and miR-5698, respectively. When the miRNA-IncRNA correlation was set to be greater than 0.8, a total of 31 IncRNAs were found and they jointly regulated 36 miRNAs, among which the top five IncRNAs that regulated the number of miRNAs were CDCA3, SCAMP1, RPL18, NDUFA4, and MGST1, respectively. The results (Fig. 4B) showed that IncRNA and miRNA were highly clustered, among which miRNA-94, miRNA-2277 and miRNA-5192 had the most IncRNA binding sites.

Drug prediction of DEGs

The DGIdb database provides the association between genes and their matching known or potential drugs. However, it cannot guarantee that any given drug gene association represents an appropriate therapeutic intervention. After processing by the DGIdb database, we screened the approved drugs related to neuropathic pain from 8,251 results based on the keyword “neuropathic” (Supplementary Table 1). Most of these drugs are some arthritis, antiepileptic drugs and sedatives. The effects of the drug include treatment of osteoarthritis, rheumatoid arthritis, treatment of tonic clonic seizures, regulation of heart rate, body temperature, blood pressure, appetite, attention, mood and reactions related to alertness or alarm conditions.

Discussion

Neuropathic pain is the main form of chronic pain. Neuropathic pain is mainly caused by damage and disorder of the nervous system. Therefore, it is important to investigate the pathological mechanism of
NP and identify effective therapeutic targets.

Recently, several studies have been highlighted the function and clinical significance of non-coding RNA in NP (6, 7). However, RNA crosstalk on NP has yet been resolved. This work combined with IncRNA, miRNA, and mRNA expression profiles and constructed a IncRNA-miRNA-mRNA regulatory network is to provide new ideas for post-transcriptional gene regulation of NP. In addition, with the help of big data mining and public database annotations, we explored the key molecules of multiple physiological and pathological processes of NP and identified several potential NP drug targets by reviewing the previous work.

The identified DEmiRs and DEGs have not been reported in the previous study related to the pathogenesis of neuropathic pain. MiR-940 is mainly related to proliferation and metastasis of cancer, such as gastric cancer (11), endometrial carcinoma (12), thyroid cancer (13), and cervical cancer (14). Interestingly, miR-940 also regulates the inflammatory response in osteoarthritis (OA) (15) and spinal cord injury (16). IncRNA XIST enhances ANLN by up-regulating miR-200c-3p, promotes the chemical resistance of breast cancer cells to doxorubicin and provides a potential new therapeutic target for the breast (17). The exosomes rich in miR-2277-30p tend to have a high abundance of β4 and lead to a cancer promoting effect (18). The serum levels of miR-5689 were significantly correlated with overall survival after initiation of eribulin treatment, providing an evidence that serum miRNA can serve as biomarkers for the predicting the development of new distant metastasis (19). These studies to a certain extent illustrate that the DEmiRs we identified have potential research value in diseases, especially cancer. In addition, these results also need to be further verified by later work.

Similarly, the IncRNA found in this article has not been fully reported in previous studies. It is reported that knockdown of IncRNA SCAMP1 suppressed malignant biological behaviors of glioma cells through regulating the miR-499a-5p/LMX1A/NLRC5 pathway (20). Additionally, SCAMP1 could be bound with miR-137 and accelerate the progression of ovarian cancer (OC) (21). Zhang, Xu (22) constructed a completing endogenous RNA (ceRNA) to explore the molecular mechanism of cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC) cells. They found that MSTRG51053.2 IncRNA may be used as ceRNA for miR-432-5p to regulate DDP resistance in non-small cell lung cancer.

According to the recommendations from the international association (23), SNRI–duloxetine, venlafaxine, tricyclic antidepressants, and Gabapentin, pregabalin are recommended for first-line; while Capsaicin 8% patches, Lidocaine (lignocaine) patches, and Tramadol are recommended for second-line; and the strong opioids are recommended for the third line. Most of the drugs that were predicted in our study are arthritis, antiepileptic drugs, and sedatives, indicating that the identified genes were associated with the pathogenic mechanism of NP. However, it does not mean that we can use these predicated drugs in the clinic since there needs more research about these genes.

However, there are still some limitations of this study. First of all, we found that IncRNAs and microRNAs were related to neuropathic pain based on the GEO database, but it still needs to be verified by PCR analysis or immunoblotting. Secondly, the IncRNA-microRNAs-mRNA network constructed in our work
could not indicate whether these RNAs co-express altogether in the same tissue. Finally, the specificity of the identified DElnc, DEmiRs and DEGs of neuropathic pain needs to be verified in further study.

Conclusions

This study was constructed a lncRNA-microRNAs-mRNA network correlated to neuropathic pain and identified potential disease targets through the integration of the microarray data and rigorous analysis. Our methods can be provided a new idea and references for further study of the pathological mechanism of NP. In addition, this study will contribute to the discovery of new biomarkers or treatments that can improve the prognosis of neuropathic pain and reduce the risk of disease.

Abbreviations

NP, Neuropathic pain; lncRNA, Long non-protein-coding RNA; XIST, X inactive-specific transcript; miRNA, MicroRNA; PPI, protein-protein interaction; DAVID, Database for Annotation, Visualization and Integrated Discovery; DEG, Differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene ontology

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Data availability

All data generated or analyzed during this study are included in this published article. Data is available at NCBI GEO: GSE107180, GSE145199, and GSE24982.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors received no funding for this work.

Authors’ contributions
HZ analyzed the data, prepared figures and wrote the manuscript. LL and ZS analyzed the data and performed the experiments. DZ conceived and designed the study. All authors have read and approved the final version of the manuscript.

Acknowledgements

Not applicable.

References

1. Gaskin DJ, Richard P. The economic costs of pain in the United States. The journal of pain : official journal of the American Pain Society. 2012;13(8):715-24.

2. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599-606.

3. Wei M, Li L, Zhang Y, Zhang ZJ, Liu HL, Bao HG. LncRNA X inactive specific transcript contributes to neuropathic pain development by sponging miR-154-5p via inducing toll-like receptor 5 in CCI rat models. Journal of cellular biochemistry. 2018.

4. Liu S, Zou L, Xie J, Xie W, Wen S, Xie Q, et al. LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X7 receptor in dorsal root ganglia. Molecular brain. 2016;9:44.

5. Zhou J, Xiong Q, Chen H, Yang C, Fan Y. Identification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis. Frontiers in molecular neuroscience. 2017;10:91.

6. Dayer CF, Luthi F, Le Carré J, Vuistiner P, Terrier P, Benaim C, et al. Differences in the miRNA signatures of chronic musculoskeletal pain patients from neuropathic or nociceptive origins. PloS one. 2019;14(7):e0219311.

7. Pan Z, Shan Q, Gu P, Wang XM, Tai LW, Sun M, et al. miRNA-23a/CXCR4 regulates neuropathic pain via directly targeting TXNIP/NLRP3 inflammasome axis. Journal of neuroinflammation. 2018;15(1):29.

8. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols. 2009;4(1):44-57.

9. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research. 2009;37(1):1-13.

10. Cotto KC, Wagner AH, Feng YY, Kiwala S, Coffman AC, Spies G, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic acids research. 2018;46(D1):D1068-d73.

11. Fan Y, Che X, Hou K, Zhang M, Wen T, Qu X, et al. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression. Experimental cell research. 2018;373(1-2):180-7.
12. Zhou Z, Xu YP, Wang LJ, Kong Y. miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1. Bioscience reports. 2019;39(6).

13. Sun D, Chen L, Lv H, Gao Y, Liu X, Zhang X. Circ_0058124 Upregulates MAPK1 Expression to Promote Proliferation, Metastasis and Metabolic Abilities in Thyroid Cancer Through Sponging miR-940. OncoTargets and therapy. 2020;13:1569-81.

14. Xiao X, Zhang Y, Lin Q, Zhong K. The better effects of microbubble ultrasound transfection of miR-940 on cell proliferation inhibition and apoptosis promotion in human cervical cancer cells. OncoTargets and therapy. 2019;12:6813-24.

15. Cao J, Liu Z, Zhang L, Li J. miR-940 regulates the inflammatory response of chondrocytes by targeting MyD88 in osteoarthritis. Molecular and cellular biochemistry. 2019;461(1-2):183-93.

16. Wang B, Shen PF, Qu YX, Zheng C, Xu JD, Xie ZK, et al. miR-940 promotes spinal cord injury recovery by inhibiting TLR4/NF-κB pathway-mediated inflammation. European review for medical and pharmacological sciences. 2019;23(8):3190-7.

17. Zhang M, Wang F, Xiang Z, Huang T, Zhou WB. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clinical and experimental pharmacology & physiology. 2020.

18. Gao Q, Lei F, Zeng Q, Gao Z, Niu P, Junnan, et al. Functional Passenger-Strand miRNAs in Exosomes Derived from Human Colon Cancer Cells and Their Heterogeneous Paracrine Effects. International journal of biological sciences. 2020;16(6):1044-58.

19. Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S, et al. Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PloS one. 2019;14(9):e0222024.

20. Zong Z, Song Y, Xue Y, Ruan X, Liu X, Yang C, et al. Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway. Journal of cellular and molecular medicine. 2019;23(8):5048-62.

21. Song R, Liu Z, Lu L, Liu F, Zhang B. Long Noncoding RNA SCAMP1 Targets miR-137/CXCL12 Axis to Boost Cell Invasion and Angiogenesis in Ovarian Cancer. DNA and cell biology. 2020;39(6):1041-50.

22. Zhang J, Xu C, Gao Y, Wang Y, Ding Z, Zhang Y, et al. A Novel Long Non-coding RNA, MSTRG.51053.2 Regulates Cisplatin Resistance by Sponging the miR-432-5p in Non-small Cell Lung Cancer Cells. Frontiers in oncology. 2020;10:215.

23. Murnion BP. Neuropathic pain: current definition and review of drug treatment. Australian prescriber. 2018;41(3):60-3.

Figures
Figure 1

Box plot of each sample distribution in GEO data before and after normalization. The blue box represented the distribution of the original data, while the red box represented the distribution of the normalized data. (A) GSE107180, (B) GSE145199 and (C) GSE24982.
Figure 2

Differential analysis of lncRNAs, miRNAs, and mRNAs, respectively. Volcano plots of lncRNAs (A), miRNAs (B) and mRNAs (C). Differentially expressed genes were screened by the criteria of |log2FC| > 1 and P-value < 0.05, the green spots represented the downregulated molecules, while the red spots represented the upregulated molecules. The top ten lncRNAs (D), miRNAs (E) and mRNAs (F) with the
smallest P-values in the upregulated and downregulated cluster were taken out respectively for the drawing of a heatmap.

Figure 3

Bubble plot of GO/KEGG analysis of the DEGs. The bubble size represented the count of differential genes, and the depth of color of the bubble represented the significance of the differential genes based on the P-values.
Figure 4

Molecular regulatory interaction network. (A) Protein-protein interaction network. Different colors represented different clusters, and the clustering result was obtained by the k-mean method. (B) lncRNA-miRNA-mRNA network. The blue node represented lncRNA, the yellow represented miRNA, and the red node represented mRNA, the red line represented the positive regulatory relationship, the blue line
represented the negative regulatory relationship, the node size represented the degree of association of the molecular with other molecules.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTable1.xlsx](#)